Colchicine use in advanced kidney disease is contraindicated or requires significant dose reduction due to risk of severe toxicity from drug accumulation.
Contraindicated in end-stage renal disease without dialysis adjustment.
Monitor CBC, renal function, and muscle enzymes regularly if used.
Onset of toxicity can be delayed due to accumulation.
Consult nephrology for individualized dosing.
Colchicine is primarily excreted unchanged by the kidneys (about 40-65% of dose). In advanced chronic kidney disease (CKD stages 4-5 or GFR <30 mL/min), renal clearance is impaired, leading to prolonged half-life and systemic accumulation of the drug and its active metabolites.
Increased risk of colchicine toxicity, including severe gastrointestinal effects (nausea, vomiting, diarrhea), bone marrow suppression (pancytopenia, leukopenia), neuromuscular toxicity (myopathy, rhabdomyolysis, neuropathy), and potentially fatal multi-organ failure.
Avoid colchicine in patients with severe renal impairment (CrCl <30 mL/min) unless benefits outweigh risks; if used, reduce dose by 75% or more (e.g., max 0.3 mg/day or less) and monitor closely for toxicity. Consider alternatives like NSAIDs or corticosteroids for gout management. Hemodialysis does not significantly remove colchicine.
Was this helpful?
The content on SafeTo is for informational purposes only and does not constitute medical, veterinary, or professional advice. Always consult with a qualified professional for specific concerns.
